Fundraising Fox
/Companies
Sign in

Bio-Path Holdings

OTC: BPTH

Bellaire, US · Wyoming corporation

Find your way into Bio-Path Holdings

Sign up to see every warm intro you have to Bio-Path Holdings

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Bio-Path Holdings team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Bio-Path Holdings is a clinical-stage biotechnology company developing antisense RNAi nanoparticle drugs as targeted, lower-toxicity cancer therapies for fragile patients ineligible for high-dose chemotherapy. Its pipeline targets blood cancers such as acute myeloid leukemia and lymphoma as well as solid tumors.

BiotechHealthtech

Founders & leadership

DPDouglas P, Morris
Douglas P, MorrisCo-Founder, Board Director, and Director of Investor Relations
PH
Peter H. NielsenExecutive
MP
Mark P. ColonneseNamed on SEC filing

Board

PD
Paul D. AubertBoard director
HW
Heath W. CleaverBoard director
AS
Aline SherwoodBoard director

Reported raises · per SEC filings

Form D private placements

$16.6M disclosed across 9 rounds · 2018–2024

▶$4MraisedOct 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul D. AubertDirector
  • Peter H. NielsenExecutive Officer, Director
  • Douglas P, MorrisDirector
  • Heath W. CleaverDirector
  • Aline SherwoodDirector
Offering amount
$4M
Amount sold
$4M
Sales commissions
$340K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Oct 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedJun 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Aline SherwoodDirector
  • Peter H. NielsenExecutive Officer, Director
  • Paul D. AubertDirector
  • Douglas P. MorrisDirector
  • Heath W. CleaverDirector
Offering amount
$4M
Amount sold
$4M
Sales commissions
$340K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jun 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedApr 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter H. NielsenExecutive Officer, Director
  • Heath W. CleaverDirector
  • Paul D. AubertDirector
  • Douglas P. MorrisDirector
  • Aline SherwoodDirector
Offering amount
$1.3M
Amount sold
$1.3M
Sales commissions
$102.8K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Apr 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$317.9KraisedApr 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter H. NielsenExecutive Officer, Director
  • Heath W. CleaverDirector
  • Aline SherwoodDirector
  • Douglas P. MorrisDirector
  • Paul D. AubertDirector
Offering amount
$317.9K
Amount sold
$317.9K
Sales commissions
$25.5K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.3MraisedNov 2022 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter H. NielsenExecutive Officer, Director
  • Heath W. CleaverDirector
  • Paul D. AubertDirector
  • Douglas P. MorrisDirector
  • Aline SherwoodDirector
Offering amount
$2.3M
Amount sold
$2.3M
Sales commissions
$140K
Placement agents
ROTH Capital Partners, LLC
First sale
Nov 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.4MraisedMar 2019 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark P. ColonneseDirector
  • Douglas P. MorrisDirector
  • Heath W. CleaverDirector
  • Peter H. NielsenExecutive Officer, Director
  • Paul D. AubertDirector
Offering amount
$1.4M
Amount sold
$1.4M
Sales commissions
$1.3M
Placement agents
H.C. Wainwright & Co., LLC
First sale
Mar 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$83.8KraisedJan 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas P. MorrisDirector
  • Heath W. CleaverDirector
  • Paul D. AubertDirector
  • Mark P. ColonneseDirector
  • Peter H. NielsenExecutive Officer, Director
Offering amount
$83.8K
Amount sold
$83.8K
Sales commissions
$42.5K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jan 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$987.7KraisedJan 2019 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas P. MorrisDirector
  • Mark P. ColonneseDirector
  • Paul D. AubertDirector
  • Peter H. NielsenExecutive Officer, Director
  • Heath W. CleaverDirector
Offering amount
$987.7K
Amount sold
$987.7K
Sales commissions
$137.4K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jan 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Bio-Path Holdings Reports Full Year 2024 Financial Results - BioSpacebiospace.com · Mar 2025Media - BioPath Holdingsbiopathholdings.com · Sep 2021

Frequently asked questions

What does Bio-Path Holdings do?
Bio-Path Holdings is a clinical-stage biotechnology company developing antisense RNAi nanoparticle drugs as targeted, lower-toxicity cancer therapies for fragile patients ineligible for high-dose chemotherapy. Its pipeline targets blood cancers such as acute myeloid leukemia and lymphoma as well as solid tumors.
Who founded Bio-Path Holdings?
Bio-Path Holdings was founded by Douglas P, Morris.
How much funding has Bio-Path Holdings raised?
Bio-Path Holdings has disclosed $16.6M raised across 9 rounds.
Where is Bio-Path Holdings headquartered?
Bio-Path Holdings is headquartered in Bellaire, US.